Research guides

MOTS-c: what the research says

A peptide encoded in mitochondrial rather than nuclear DNA, whose discovery mattered more than the molecule. The founding mouse work, and the ten years since.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

MOTS-c is scientifically the most interesting compound in this file and clinically the least evidenced, and both facts come from the same place: it was discovered recently, as part of establishing that a whole category of signalling molecule exists.

What the molecule is

A 16-amino-acid peptide encoded not in the cell nucleus but in mitochondrial DNA — one of a small group of mitochondrial-derived peptides.

Why the discovery mattered

Mitochondria were understood as organelles that produce energy and respond to signals from the rest of the cell. Finding that they encode peptides which act on the nucleus and on metabolism reverses part of that relationship: the organelle signals outward, not only inward. The founding paper is cited as much for establishing that category as for anything about this particular peptide.

What the founding work reported

Published mouse and cell work reported that the peptide activates AMPK — the cell's low-energy sensor — and moves into the nucleus to change gene expression in response to metabolic stress. In mice it prevented diet-induced weight gain and insulin resistance. A commentary published alongside it in the same issue framed it as a mitochondrially encoded hormone.

What has not followed

Ten years on there is no published randomised controlled trial in humans, no approved indication and no clinical development programme with published results. The compound is a genuine and well-cited piece of cell biology whose translation has not happened, and describing it in terms of what it does for people runs far ahead of the evidence.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

  1. Lee et al. (2015)Cell Metabolism · 21(3):443–54

    Reported that the peptide activates AMPK signalling and prevents high-fat-diet-induced weight gain and insulin resistance, and that it is encoded in mitochondrial DNA.

    mouse and HEK293 cells Source

  2. Zarse & Ristow (2015)Cell Metabolism · 21(3):355–6

    A commentary published alongside the founding paper, framing the finding as the identification of a mitochondrially encoded hormone acting on obesity and insulin resistance.

    commentary Source

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

  • The `adverse` list is empty because no toxicology or safety study of this peptide has been published. Nobody has looked, rather than having looked and found nothing.
  • No randomised controlled trial in humans has been published for any indication, and there is no clinical development programme with published results.
  • The metabolic findings are in mice on a high-fat diet. Diet-induced obesity in rodents is a model, and its record at predicting human metabolic outcomes is mixed.
  • AMPK is a central metabolic regulator active in essentially every tissue. What sustained activation of it by an exogenous peptide does over time has not been characterised.
  • It holds no marketing authorisation in any jurisdiction.
  • Human observational work associating endogenous levels of the peptide with metabolic states is a different kind of evidence from administering it, and the two are frequently conflated.

Common questions

What makes MOTS-c unusual?
It is encoded in mitochondrial DNA rather than in the nucleus. Its discovery helped establish that mitochondria encode signalling molecules acting on the rest of the cell, which is why the founding paper is cited as much for the category as for the peptide.
What did the MOTS-c research find?
The founding mouse and cell work reported that it activates AMPK, moves into the nucleus to alter gene expression under metabolic stress, and prevented diet-induced weight gain and insulin resistance in mice.
Has MOTS-c been tested in humans?
No randomised controlled trial has been published, and there is no clinical development programme with published results. It has been studied in humans observationally, which is a different kind of evidence.
What is AMPK?
The cell's low-energy sensor — a central metabolic regulator active in essentially every tissue. That breadth is why sustained activation by an exogenous peptide is a question the published work does not answer.
Is MOTS-c approved anywhere?
No. It is supplied here as a laboratory reagent for in-vitro research and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

Related articles

All guides